Rhumbline Advisers Gritstone Bio, Inc. Call Options Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GRTS
# of Institutions
75Shares Held
37.5MCall Options Held
1.46MPut Options Held
168K-
Redmile Group, LLC San Francisco, CA5.11MShares$153,2310.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.64MShares$139,3170.0% of portfolio
-
Morgan Stanley New York, NY4.45MShares$133,6200.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA3.56MShares$106,8344.9% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL3.46MShares$103,8440.01% of portfolio
About Gritstone bio, Inc.
- Ticker GRTS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,006,896
- Market Cap $2.19M
- Description
- Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...